Gilead Committed to Rolling Out HIV Prevention Jab in Africa, awaits FDA approval
Gilead Sciences is poised to supply its groundbreaking twice-yearly injection, lenacapavir, to low-income countries, pending FDA approval, writes Catherine Murombedzi. The twice-yearly jab has shown nearly 100% effectiveness in preventing HIV infection in large trials, sparking hope that it could help end the 44-year-old. The Food and Drug Administration’s approval is the crucial…